
TTRX Stock Forecast & Price Target
TTRX Analyst Ratings
Bulls say
Turn Therapeutics is a clinical-stage biotechnology and medical device development company with a proprietary platform technology called PermaFusion that enhances drug performance. The company is focused on developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases, with its lead program, GX-03, being evaluated for moderate-to-severe eczema. Turn has also secured financing through milestone-based funding and has potential for pipeline expansion and partnerships. Its focus on capital efficiency and rapid clinical translation, coupled with its proprietary technology and IP, make it an attractive investment with multiple shots on goal.
Bears say
Turn Therapeutics is a clinical-stage biotechnology and medical device development company with limited revenue potential, primarily focused on developing topical treatments for inflammatory skin diseases. Their current programs are in the early stages and are heavily reliant on ongoing clinical trials and potential partnerships for future growth. The recent financing deal may provide some financial stability, but does not guarantee immediate cash inflow and the success of their programs will depend on data generated in ongoing studies.
This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares